NBTX — Nanobiotix SA Income Statement
0.000.00%
Last trade - 00:00
- $275.47m
- $246.31m
- €30.06m
- 22
- 17
- 46
- 19
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.068 | 0.05 | 0.01 | 0 | 30.1 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 46.8 | 36.5 | 52.6 | 53.6 | 56.6 |
Operating Profit | -46.8 | -36.4 | -52.6 | -53.6 | -26.5 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -50.9 | -33.6 | -47 | -57 | -39.6 |
Provision for Income Taxes | |||||
Net Income After Taxes | -50.9 | -33.6 | -47 | -57 | -39.7 |
Net Income Before Extraordinary Items | |||||
Net Income | -50.9 | -33.6 | -47 | -57 | -39.7 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -50.9 | -33.6 | -47 | -57 | -39.7 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.35 | -1.38 | -1.35 | -1.51 | -1.08 |
Dividends per Share |